Autoimmune aspects of vitiligo.
Vitiligo is a depigmenting disorder characterised by the loss of melanocytes from the cutaneous epidermis. Although the exact cause of the condition remains to be established, an autoimmune aetiology has been suggested and several observations support this theory. These will be the topic of discussion in this review. In brief, the disease is frequently associated with other disorders which have an autoimmune origin such as autoimmune thyroiditis and insulin-dependent diabetes mellitus. Furthermore, circulating antibodies and T lymphocytes which react against melanocyte antigens are present in the sera of a significant proportion of vitiligo patients compared with healthy individuals. Immunosuppressive therapies which are reasonably effective in treating the condition, well-studied animal models of the disease as well as the association of vitiligo with MHC antigens, all add credence to the hypothesis that immune mechanisms play a role in the development of vitiligo.
Kemp
E H
EH
Division of Clinical Sciences, Northern General Hospital, University of Sheffield, UK. e.h.kemp@sheffield.ac.uk
Waterman
E A
EA
Weetman
A P
AP
D000818:Animals; D001323:Autoantibodies / Q000096:biosynthesis; D001327:Autoimmune Diseases / Q000150:complications; D015551:Autoimmunity; D004195:Disease Models, Animal; D006801:Humans; D007111:Immunity, Cellular; D007125:Immunogenetics; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008544:Melanocytes / Q000276:immunology; D008545:Melanoma / Q000150:complications / Q000276:immunology; D012878:Skin Neoplasms / Q000150:complications / Q000276:immunology; D014820:Vitiligo / Q000150:complications / Q000188:drug therapy / Q000209:etiology / Q000276:immunology*
D001323:Autoantibodies; D007166:Immunosuppressive Agents